Merck licenses antidepressant candidate to Cerecor

04/22/2013 | Pharmaceutical Business Review Online

Merck & Co. granted Cerecor exclusive global rights to develop and market the experimental drug MK-0657, a small molecule NMDA receptor subunit 2B antagonist for all clinical indications. Cerecor plans to develop the compound as a treatment for severe refractory depression and suicidal thoughts and behavior. The deal entitles Merck to milestone fees and royalties.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA